Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wesley Clark

Adult Reconstructive Orthopaedic Surgery New Orleans, LA Medical Doctor

NPI 1225220551 CMS profile 191427

2731 Napoleon Ave, New Orleans, LA 70115

Open in the dashboard

General payments

$153,179

324 records reported · program years 2019–2025

Research payments

$27,145

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wesley Clark of New Orleans, LA is reported in the CMS Open Payments database as having received $153,179 across 324 general payments and $27,145 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,149 35
2024 General $30,272 72
2023 General $34,991 68
2022 General $33,874 57
2022 Research $750 1
2021 General $18,346 21
2021 Research $4,380 2
2020 General $5,421 24
2020 Research $3,100 4
2019 General $24,126 47
2019 Research $18,915 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wesley Clark
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Wesley Clark were reported at $6,149. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Wesley Clark Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $24,126 $1,416 $292–$9,336 $163
2020 $5,421 $647 $141–$6,474 $114
2021 $18,346 $1,073 $211–$6,497 $132
2022 $33,874 $1,217 $236–$6,299 $149
2023 $34,991 $1,082 $246–$6,818 $160
2024 $30,272 $1,575 $323–$8,944 $164
2025 $6,149 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $127,407 149 payments
  2. Lima USA, Inc. $14,708 20 payments
  3. Shalby Advanced Technologies, Inc. $5,896 15 payments
  4. Globus Medical, Inc. $1,248 18 payments
  5. Stryker Corporation $892 27 payments
  6. Davol Inc. $410 6 payments
  7. DePuy Synthes Sales Inc. $250 3 payments
  8. Horizon Therapeutics plc $249 10 payments
  9. Heron Therapeutics, Inc. $194 4 payments
  10. Medical Device Business Services, Inc. $151 2 payments
  11. Other $1,774 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $114,159 22 payments
  2. Travel and Lodging $28,302 91 payments
  3. Food and Beverage $10,717 211 payments
Products named General payments · program years 2019–2025
  1. GMK SPHERE $56,007 28 payments
  2. GMK Sphere Revision System $27,917 30 payments
  3. AMISTEM $19,526 74 payments
  4. MASTERSL $11,489 12 payments
  5. H-MAX SYSTEM $11,474 11 payments
  6. PHYSICA CR $11,041 10 payments
  7. PRIMARY SHOULDER $5,023 11 payments
  8. Acetabular Shell $4,302 8 payments
  9. Consensus Hip System $4,168 7 payments
  10. CS2 Acet. Cup Sys. - VitalitE $4,023 5 payments
  11. Other $16,788 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medacta USA, Inc. $27,145 16 payments

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

2,782

Median for Orthopedic Surgery: 203

Drug cost

$21,112

Median for Orthopedic Surgery: $1,433

Branded share of claims

17.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 440 $5,150
Gabapentin Generic 582 $4,108
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 224 $2,638
Ondansetron Odt Ondansetron Brand 138 $1,906
Diclofenac Sodium Generic 133 $1,630
Tizanidine Hcl Generic 277 $1,151
Mupirocin Generic 138 $1,016
Tramadol Hcl Generic 279 $1,015
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 94 $800
Meloxicam Generic 225 $540

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$134,482

Of which drugs: $6,275

Medicare patients

310

Average age 74

Services billed

7,619

190 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Chronic kidney disease 29%
Ischemic heart disease 26%
Depression 20%
Atrial fibrillation 19%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 27 56 $3,249
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 11 400 $2,215
Injection, methylprednisolone acetate, 1 mg J1010 Office 104 5,405 $527
Injection, methylprednisolone acetate, 40 mg J1030 Office 41 58 $250

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $12
$12 — —
Prolia
  • Amgen Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record